Multiple Sclerosis
of life in multiple sclerosis, J Clin Exp Neuropsychol, 2000;22(1):125–31.
15. Forn C, Belenguer A, Parcet-Ibars MA, Avila C, Information-processing speed is the primary deficit underlying the poor performance of multiple sclerosis patients in the Paced Auditory Serial Addition Test (PASAT), J Clin Exp Neuropsychol, 2008;30(7):789–96.
16. Parmenter BA, Shucard JL, Shucard DW, Information processing deficits in multiple sclerosis: a matter of complexity, J Int Neuropsychol Soc, 2007;13(3):417–23.
17. Parmenter BA, Shucard JL, Benedict RH, Shucard DW, Working memory deficits in multiple sclerosis: comparison between the n-back task and the Paced Auditory Serial Addition Test, J Int Neuropsychol Soc, 2006;12(5):677–87.
18. Benedict RH, Cookfair D, Gavett R, Gunther M, et al., Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS), J Int Neuropsychol Soc, 2006;12(4):549–58.
19. Rosti E, Hämäläinen P, Koivisto K, Hokkanen L, PASAT in detecting cognitive impairment in relapsing-remitting MS, Appl Neuropsychol, 2007;14(2):101–12.
20. Parmenter BA, Weinstock-Guttman B, Garg N, et al., Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test, Mult Scler, 2007;13(1):52–7.
21. Benedict RH, Duquin JA, Jurgensen S, et al., Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire, Mult Scler, 2008;14(7):940–46.
22. Rudick RA, Polman CH, Cohen JA, et al., Assessing disability progression with the Multiple Sclerosis Functional Composite, Mult Scler, 2009;15(8):984–97.
23. Brochet B, Deloire MS, Bonnet M, Set al., Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study, Mult Scler, 2008;14(9):1242–9.
24. Drake AS, Weinstock-Guttman B, Morrow SA, et al., Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test, Mult Scler, 2010;16(2):228–37.
25. Rosti-Otajärvi E, Hämäläinen P, Koivisto K, Hokkanen L, The reliability of the MSFC and its components, Acta Neurol Scand, 2008;117(6):421–7.
26. Rao SM, Neuropsychology of multiple sclerosis: a critical review, J Clin Exp Neuropsychol, 1986;8:503–42. 27. DeLuca J, Gaudino EA, Diamond BJ, et al., Acquisition
and storage deficits in multiple sclerosis, J Clin Exp Neuropsychol, 1998;20(3):376–90.
28. Stegen S, Stepanov I, Cookfair D, et al., Validity of the California Verbal Learning Test-II in multiple sclerosis, Clin Neuropsychol, 2010;24(2):189–202.
29. Kenealy PM, Beaumont JG, Lintern TC, Murrell RC, Autobiographical memory in advanced multiple sclerosis: assessment of episodic and personal semantic memory across three time spans, J Int Neuropsychol Soc, 2002;8(6):855–60.
30. Drew M, Tippett LJ, Starkey NJ, Isler RB, Executive dysfunction and cognitive impairment in a large community-based sample with Multiple Sclerosis from New Zealand: a descriptive study, Arch Clin Neuropsychol, 2008;23(1):1–19.
31. Beatty WW, Fluency in multiple sclerosis: which measure is best?, Mult Scler, 2002;8(3):261–4.
32. Simioni S, Ruffieux C, Kleeberg J, et al., Progressive decline of decision-making performances during multiple sclerosis, J Int Neuropsychol Soc, 2009;15(2):291–5.
33. Rao SM, A manual for the Brief Repeatable Battery of neuropsychological tests in multiple sclerosis, Milwaukee, Wisconsin: Medical College of Wisconsin, 1990.
34. Portaccio E, Goretti B, Zipoli V, et al.; TuSCIMS Study Group. Reliability, practice effects, and change indices for Rao’s Brief Repeatable Battery, Mult Scler, 2010;16(5):611–17.
35. Benedict RH, Fischer JS, Archibald CJ, et al., Minimal neuropsychological assessment of MS patients: a consensus approach, Clin Neuropsychol, 2002;16(3): 381–97.
36. Strober L, Englert J, Munschauer F, et al., Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS, Mult Scler, 2009;15(9):1077–84.
37. Portaccio E, Goretti B, Zipoli V, et al., A short version of Rao’s Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis, Clin Neuropsychol, 2009;23:268–75.
38. Sørensen PS, Jønsson A, Mathiesen HK, et al., The relationship between MRI and PET changes and cognitive disturbances in MS, J Neurol Sci, 2006;245(1–2):99–102.
39. Sharma R, Fischer MT, Bauer J, et al., Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction
followed by demyelination, Acta Neuropathol, 2010 Jun 8 (Epub ahead of print).
40. Calabrese M, Agosta F, Rinaldi F, et al., Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis, Arch Neurol, 2009;66(9):1144–50.
41. Amato MP, Portaccio E, Goretti B, et al., Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis, Arch Neurol, 2007;64(8):1157–61.
42. Bellmann-Strobl J, Wuerfel J, et al., Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis, Neurology, 2009;73(20):1624–7.
43. Ghaffar O, Feinstein A, APOE epsilon4 and cognitive dysfunction in multiple sclerosis: a review, J Neuropsychiatry Clin Neurosci, 2010;22(2):155–65.
44. Amato MP, Portaccio E, Zipoli V, Are there protective treatments for cognitive decline in MS?, J Neurol Sci, 2006;245(1–2):183–6.
45. Fischer JS, Priore RL, Jacobs LD, et al., Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group, Ann Neurol, 2000;48(6): 885–92.
46. Kappos L, Freedman MS, Polman CH, et al., Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurol, 2009;8:987–97.
47. Krupp LB, Christodoulou C, Melville P, et al., Donepezil improved memory in multiple sclerosis in a randomized clinical trial, Neurology, 2004;63:1579–85.
48. Cader S, Palace J, Matthews PM, Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis, J Psychopharmacol, 2009;23:686–96.
49. Cucurachi L, Immovilli P, Granella F, et al., Short- latency afferent inhibition predicts verbal memory performance in patients with multiple sclerosis, J Neurol, 2008;255:1949–56.
50. Shaygannejad V, Janghorbani M, Ashtari F, et al., Effects of rivastigmine on memory and cognition in multiple sclerosis, Can J Neurol Sci, 2008;35:476–81.
51. Langdon DW, Cognitive rehabilitation in multiple sclerosis. In: Kesselring J, Comi G, Thompson A (eds), Multiple Sclerosis: Recovery of Function and Neurorehabilitation, Cambridge University Press, 2010.
72
EUROPEAN NEUROLOGICAL REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116